EA201270715A1 - Способ получения и очистки рекомбинантной лизосомальной альфа-маннозидазы - Google Patents

Способ получения и очистки рекомбинантной лизосомальной альфа-маннозидазы

Info

Publication number
EA201270715A1
EA201270715A1 EA201270715A EA201270715A EA201270715A1 EA 201270715 A1 EA201270715 A1 EA 201270715A1 EA 201270715 A EA201270715 A EA 201270715A EA 201270715 A EA201270715 A EA 201270715A EA 201270715 A1 EA201270715 A1 EA 201270715A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alpha
mannosidase
lizosomal
obtaining
recombinant
Prior art date
Application number
EA201270715A
Other languages
English (en)
Other versions
EA022220B1 (ru
Inventor
Йенс Фогх
Клаэс Андерссон
Сесилиа Веигельт
Пиа Хюден
Хелена Реутервалль
Стефан Нильссон
Original Assignee
Сюменекс А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сюменекс А/С filed Critical Сюменекс А/С
Publication of EA201270715A1 publication Critical patent/EA201270715A1/ru
Publication of EA022220B1 publication Critical patent/EA022220B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477—Hemicellulases not provided in a preceding group
    • C12N9/2488—Mannanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01024—Alpha-mannosidase (3.2.1.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к способу очистки рекомбинантной альфа-маннозидазы, способу получения альфа-маннозидазы, композиции, включающей альфа-маннозидазу, применению композиции в качестве лекарственного препарата, применению в качестве лекарственного препарата для лечения альфа-маннозидоза и способу лечения альфа-маннозидоза и/или облегчения симптомов альфа-маннозидоза.
EA201270715A 2010-02-24 2011-02-23 Способ получения и очистки рекомбинантной лизосомальной альфа-маннозидазы EA022220B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30758710P 2010-02-24 2010-02-24
DKPA201070067 2010-02-24
PCT/DK2011/050054 WO2011103877A1 (en) 2010-02-24 2011-02-23 Process for production and purification of recombinant lysosomal alpha-mannosidase

Publications (2)

Publication Number Publication Date
EA201270715A1 true EA201270715A1 (ru) 2013-01-30
EA022220B1 EA022220B1 (ru) 2015-11-30

Family

ID=43920349

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270715A EA022220B1 (ru) 2010-02-24 2011-02-23 Способ получения и очистки рекомбинантной лизосомальной альфа-маннозидазы

Country Status (25)

Country Link
US (3) US8974780B2 (ru)
EP (2) EP2538968B1 (ru)
JP (1) JP6021647B2 (ru)
KR (1) KR101856260B1 (ru)
CN (1) CN102834111B (ru)
AU (1) AU2011220163B2 (ru)
BR (1) BR112012020934B1 (ru)
CA (1) CA2790786C (ru)
CY (1) CY1123438T1 (ru)
DK (2) DK3281636T3 (ru)
EA (1) EA022220B1 (ru)
ES (1) ES2652330T3 (ru)
FR (1) FR18C1038I2 (ru)
HK (1) HK1179869A1 (ru)
HR (1) HRP20171736T1 (ru)
HU (2) HUE037943T2 (ru)
LT (2) LT2538968T (ru)
NL (1) NL300948I2 (ru)
NO (2) NO2538968T3 (ru)
NZ (1) NZ601790A (ru)
PL (2) PL3281636T3 (ru)
PT (1) PT2538968T (ru)
RS (1) RS60983B1 (ru)
SI (2) SI2538968T1 (ru)
WO (1) WO2011103877A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9310344B2 (en) 2013-06-14 2016-04-12 Dionex Corporation HILIC/anion-exchange/cation-exchange multimodal media
US9169331B2 (en) * 2012-12-21 2015-10-27 Dionex Corporation Separation of glycans by mixed-mode liquid chromatography
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN111100196B (zh) * 2019-11-08 2021-07-13 上海交通大学 一种生物活性多肽qilsvpgwtysr及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63327A (en) * 1981-07-16 1985-11-29 Yeda Res & Dev Production of interferon beta1 and alpha-phage recombinants for its production in host bacteria
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4320870B2 (ja) 1999-10-18 2009-08-26 住友化学株式会社 （＋）−トランス第一菊酸の製造方法
GB0007651D0 (en) * 2000-03-29 2000-05-17 Ascorbex Ltd Gene sequence
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
WO2002099092A2 (en) * 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
US7507573B2 (en) * 2003-11-14 2009-03-24 Vib, Vzw Modification of protein glycosylation in methylotrophic yeast
NZ576986A (en) 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
WO2005077093A2 (en) 2004-02-06 2005-08-25 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
PL1740204T3 (pl) * 2004-04-01 2018-08-31 Chiesi Farmaceutici S.P.A. Lecznicze zastosowanie alfa-mannozydazy
CN101410408A (zh) 2006-04-04 2009-04-15 希尔制药爱尔兰有限责任公司 用于浓缩多肽的方法
PL2631242T3 (pl) * 2006-04-04 2023-03-20 Takeda Pharmaceutical Company Limited Sposób zatężania polipeptydu
AU2008274195B2 (en) 2007-07-11 2013-09-05 Novo Nordisk A/S Purification of factor VIII using a mixed-mode or multimodal resin

Also Published As

Publication number Publication date
CN102834111B (zh) 2014-11-12
HUS1800037I1 (hu) 2018-09-28
EA022220B1 (ru) 2015-11-30
CN102834111A (zh) 2012-12-19
US20120308549A1 (en) 2012-12-06
EP3281636B1 (en) 2020-08-05
LTC2538968I2 (lt) 2019-11-11
HRP20171736T1 (hr) 2018-01-26
BR112012020934B1 (pt) 2021-07-13
BR112012020934A8 (pt) 2018-02-06
NO2018032I1 (no) 2018-09-14
JP2013520184A (ja) 2013-06-06
DK2538968T3 (en) 2017-12-11
FR18C1038I2 (fr) 2019-10-11
US20150306186A1 (en) 2015-10-29
NL300948I2 (nl) 2019-02-27
DK3281636T3 (da) 2020-09-21
NO2538968T3 (ru) 2018-03-31
US20180036387A1 (en) 2018-02-08
PT2538968T (pt) 2018-01-23
AU2011220163A1 (en) 2012-08-30
EP2538968B1 (en) 2017-11-01
PL3281636T3 (pl) 2021-03-08
US10159718B2 (en) 2018-12-25
SI3281636T1 (sl) 2020-11-30
CA2790786C (en) 2019-09-24
CY1123438T1 (el) 2021-05-05
RS60983B1 (sr) 2020-11-30
AU2011220163B2 (en) 2015-05-28
LTPA2018512I1 (lt) 2018-10-10
JP6021647B2 (ja) 2016-11-09
US8974780B2 (en) 2015-03-10
NZ601790A (en) 2014-03-28
HK1179869A1 (en) 2013-10-11
EP3281636A1 (en) 2018-02-14
PL2538968T3 (pl) 2018-04-30
SI2538968T1 (en) 2018-04-30
ES2652330T3 (es) 2018-02-01
KR101856260B1 (ko) 2018-05-09
EP2538968A1 (en) 2013-01-02
FR18C1038I1 (ru) 2018-11-02
WO2011103877A1 (en) 2011-09-01
HUE037943T2 (hu) 2018-09-28
KR20120128647A (ko) 2012-11-27
BR112012020934A2 (pt) 2017-02-21
LT2538968T (lt) 2018-01-10
CA2790786A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
EA201200977A1 (ru) Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами
EA201201374A1 (ru) Лечение атаксии-телеангиэктазии
EA201490853A1 (ru) Противовирусные соединения
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
EA201270616A1 (ru) Ингибиторы вируса гепатита с
EA201891264A3 (ru) Антагонисты st2l и способы их применения
EA201270575A1 (ru) Соединения
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EA201301019A1 (ru) Бензодиоксановые ингибиторы продуцирования лейкотриена
EA201691461A1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201200794A1 (ru) Триазолопиридины
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
EA201690521A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA201301181A1 (ru) Триазолопиридины
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
EA201200999A1 (ru) Способы лечения рака молочной железы
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств
EA201171435A1 (ru) Твердые фармацевтические композиции и способы их получения
EA201400748A1 (ru) Композиция для обработки семян

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment